



Universiteit  
Leiden  
The Netherlands

## Long-term visit-to-visit variability in hemoglobin A1c and kidney-related outcomes in persons with diabetes

Xu, Y.; Dong, S.J.; Fu, E.L.; Sjölander, A.; Grams, M.E.; Selvin, E.; Carrero, J.J.

### Citation

Xu, Y., Dong, S. J., Fu, E. L., Sjölander, A., Grams, M. E., Selvin, E., & Carrero, J. J. (2023). Long-term visit-to-visit variability in hemoglobin A1c and kidney-related outcomes in persons with diabetes. *American Journal Of Kidney Diseases*, 82(3), 267-278.  
doi:10.1053/j.ajkd.2023.03.007

Version: Publisher's Version  
License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)  
Downloaded from: <https://hdl.handle.net/1887/3729564>

**Note:** To cite this publication please use the final published version (if applicable).

## Long-term Visit-to-Visit Variability in Hemoglobin A<sub>1c</sub> and Kidney-Related Outcomes in Persons With Diabetes



Yang Xu, Shujie Dong, Edouard L. Fu, Arvid Sjölander, Morgan E. Grams, Elizabeth Selvin, and Juan Jesus Carrero

**Rationale & Objective:** To characterize associations between long-term visit-to-visit variability of hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) and risk of adverse kidney outcomes in patients with diabetes.

**Study Design:** Observational study.

**Setting & Participants:** 93,598 adults with diabetes undergoing routine care in Stockholm, Sweden.

**Exposures and Predictors:** Categories of baseline and time-varying HbA<sub>1c</sub> variability score (HVS, the percentage of total HbA<sub>1c</sub> measures that vary by >0.5% [5.5 mmol/mol] during a 3-year window): 0-20%, 21%-40%, 41%-60%, 61%-80%, and 81%-100%, with 0-20% as the reference group.

**Outcome:** Chronic kidney disease (CKD) progression (composite of >50% estimated glomerular filtration rate [eGFR] decline and kidney failure), acute kidney disease (AKI by clinical diagnosis or transient creatinine elevations according to KDIGO criteria), and worsening of albuminuria.

**Analytical Approach:** Multivariable Cox proportional hazards regression.

**Results:** Compared with persons showing low HbA<sub>1c</sub> variability (HVS 0-20%), any increase in variability was associated with a higher risk of adverse kidney outcomes beyond mean HbA<sub>1c</sub>. For example, for patients with a baseline HbA<sub>1c</sub> variability of 81%-100%, the adjusted HR was 1.6 (95% CI, 1.47-1.74) for CKD progression, 1.23 [1.16-1.3] for AKI, and 1.28 [1.21-1.36] for worsening of albuminuria. The results were consistent across subgroups (diabetes subtypes, baseline eGFR, or albuminuria categories), in time-varying analyses and in sensitivity analyses including time-weighted average HbA<sub>1c</sub> or alternative metrics of variability.

**Limitations:** Observational study, limitations of claims data, lack of information on diet, body mass index, medication changes, and diabetes duration.

**Conclusions:** Higher long-term visit-to-visit HbA<sub>1c</sub> variability is consistently associated with the risks of CKD progression, AKI, and worsening of albuminuria.

Complete author and article information provided before references.

Correspondence to Y. Xu (xuyang\_pucui@bjmu.edu.cn)

Am J Kidney Dis. 82(3):267-278. Published online May 13, 2023.

doi: 10.1053/j.ajkd.2023.03.007

© 2023 by the National Kidney Foundation, Inc.

Glycated hemoglobin (HbA<sub>1c</sub>) is routinely monitored for glycemic control in persons with diabetes, and intensive glycemic control is beneficial to both macro- and microvascular complications.<sup>1-3</sup> There are 2 different components of glycemic variability: short-term over days

### Editorial, p. 254

to weeks, and long-term, which may be ascertained by calculating visit-to-visit fluctuations of HbA<sub>1c</sub> over months to years. The latter is closer to the standard monitoring procedures for patients in routine clinical care and may inform clinical decisions. Guidelines focus on keeping HbA<sub>1c</sub> levels below target thresholds; however, there is growing awareness that variability in HbA<sub>1c</sub> may be an independent risk factor for diabetes complications.<sup>4-7</sup>

Between 20% and 40% of patients with diabetes develop chronic kidney disease (CKD).<sup>8-10</sup> Some but not all previous studies have observed an association between HbA<sub>1c</sub> variability and the risk of developing CKD or worsening of albuminuria.<sup>11-20</sup> The identified limitations were, in general, low sample sizes and use of nonstandard outcome definitions. Further, they were mostly performed in clinical trials or prospective research cohorts, which may not be

generalizable to the heterogeneous general population seeking health care. Acute kidney injury (AKI) is also common in patients with diabetes,<sup>21,22</sup> leading to poor outcomes and high health care costs.<sup>23</sup> We recently showed that single high HbA<sub>1c</sub> levels were associated with the risk of developing AKI.<sup>24</sup> Whether long-term HbA<sub>1c</sub> fluctuations are also associated with the risk of AKI is unknown.

Rigorous ascertainment of long-term glycemic variability may provide additional value in considering the likelihood of future kidney complications. If variability is important above and beyond the average levels of HbA<sub>1c</sub>, this could suggest that specific lifestyle modifications or pharmacological preventative strategies are warranted. In this study, we used routine care data from the region of Stockholm, Sweden, to examine the associations between long-term visit-to-visit variability of HbA<sub>1c</sub> with adverse kidney outcomes.

### Methods

#### Data Source and Study Population

The study population consisted of individuals included in the Stockholm Creatinine Measurements (SCREAM) project, a health care utilization cohort including all residents

**PLAIN-LANGUAGE SUMMARY**

The evidence for current guideline recommendations derives from clinical trials that focus on a single HbA<sub>1c</sub> as the definitive measure of efficacy of an intervention. However, long-term visit-to-visit fluctuations of HbA<sub>1c</sub> may provide additional value in the prediction of future kidney complications. We evaluated the long-term fluctuations in glycemic control in almost 100,000 persons with diabetes undergoing routine care in Stockholm, Sweden. We observed that higher long-term HbA<sub>1c</sub> fluctuation is consistently associated with the risks of chronic kidney disease progression, worsening of albuminuria and acute kidney injury. This finding supports a role for long-term glycemic variability in the development of kidney complications and illustrates the potential usefulness of this metric for risk stratification at the bedside beyond a single HbA<sub>1c</sub> test.

from Stockholm, Sweden.<sup>25</sup> The region of Stockholm had a population of 2.3 million citizens in 2019 and has a universal tax-funded health care access. Using the personal identification number of each citizen, laboratory values were linked with (1) regional administrative databases with complete information on demographic data, migration procedures, health care use, and diagnoses; (2) national databases run by the Swedish National Board of Welfare with complete information on vital status and filled prescriptions at Swedish pharmacies; and (3) the Swedish Renal Registry (<https://www.medscinet.net/snr/>), a nationwide quality registry with validated cases of kidney replacement therapy (KRT). All linked registries are considered of high quality with no or minimal loss to follow-up.<sup>26</sup> The study was approved by the regional ethics review boards and the Swedish National Board of Health and Welfare, who deemed that informed consent was not needed and provided deidentified data to the authors.

In Sweden, patients with type 1 diabetes are generally followed in specialist care and type 2 diabetes in primary care. Patients are recurrently offered culturally adapted education programs on lifestyle modifications and how to self-monitor blood glucose. Patients with type 2 diabetes are provided with self-monitoring finger prick devices. Patients with type 1 diabetes or with type 2 diabetes who have repeated episodes of hypo- or hyperglycemia are provided with subcutaneous glucose sensors.<sup>27</sup> LIBRE-type glucose monitoring is almost exclusively used by patients with type 1 diabetes. If HbA<sub>1c</sub> is stable, the standard monitoring recommendations include 1 annual visit to a general practitioner (for type 2 diabetes) or endocrinologist/diabetologist (for type 1 diabetes), and 1-4 visits per year to a specialized diabetes nurse.<sup>28</sup> Before these visits, the usual laboratory tests and clinical examinations are

performed (such as HbA<sub>1c</sub>, lipids, albuminuria, glomerular filtration rate, or blood pressure). The cost of all prescribed medications is covered by the Swedish government.

We identified all adult (>18 years old) patients in SCREAM between January 1, 2006, to December 31, 2019, with a diagnosis of type 1 or 2 diabetes. Patients with at least 1 annual outpatient HbA<sub>1c</sub> test in 3 consecutive years were included; all HbA<sub>1c</sub> tests performed during those 3 years were used to calculate HbA<sub>1c</sub> variability. The index date where follow-up started for each included patient was set at January 1 of the year after the HbA<sub>1c</sub> variability calculation period. Patients with missing information on age, sex, and estimated glomerular filtration rate (eGFR) or with kidney failure (initiation of dialysis or kidney transplantation or eGFR < 15 mL/min/1.73 m<sup>2</sup>) were excluded. A flow chart of the patient selection is illustrated in Figure S1.

**Exposure: HbA<sub>1c</sub> Variability**

The study exposure was HbA<sub>1c</sub> variability, investigated as a time-fixed and time-varying exposure. In the time-fixed design, baseline HbA<sub>1c</sub> variability was calculated from all outpatient HbA<sub>1c</sub> tests during the 3-year eligibility window that preceded baseline. In the time-varying design, 3-year HbA<sub>1c</sub> variability was recalculated at each new outpatient HbA<sub>1c</sub> test during follow-up (Fig S2). The variability of HbA<sub>1c</sub> was calculated as the HbA<sub>1c</sub> variability score (HVS). HVS ranges from 0 to 100% and is defined as the percentage of total HbA<sub>1c</sub> measures that differed by 0.5% (5.5 mmol/mol) or more compared with the previous HbA<sub>1c</sub> measurement.<sup>6</sup> For example, if a person had the following sequence of HbA<sub>1c</sub> values of 7.1%, 6.4%, 6.6%, 7.2%, 7.5%, and 6.9%, the number of measures that differed by ≥0.5% was 3 and the HVS would be 60% [ $3/5 \times 100$ ]. We used increments of 0.5% (5.5 mmol/mol) in HbA<sub>1c</sub> as an accepted indicator of a clinically significant difference in glucose exposure. HVS was grouped into 5 categories: 0-20%, 21%-40%, 41%-60%, 61%-80%, and 81%-100%, with 0-20% as the reference group.

**Assessment of Covariates**

In the time-fixed analyses, covariates were assessed at index date. In time-varying analyses, all covariates except age and sex were updated at each subsequent measure of HbA<sub>1c</sub>. Covariates included age, sex, calendar year, diabetes type, diabetes complications, comorbidities, ongoing medications, laboratory measurements, and health care utilization in the year prior as a measure of overall disease burden. Detailed definitions are shown in Tables S1 and S2.

Baseline HbA<sub>1c</sub> was defined as the average of outpatient HbA<sub>1c</sub> values during the 3-year eligibility window that preceded baseline, whereas albuminuria, eGFR, and blood lipids were defined as the most recent value during the 3-year eligibility window that preceded baseline. At each subsequent HbA<sub>1c</sub> measurement, these covariates were time-updated in the same manner. The eGFR stages were

defined according to KDIGO categories as G1 ( $\geq 90$  mL/min/ $1.73$  m<sup>2</sup>), G2 (60–89 mL/min/ $1.73$  m<sup>2</sup>), G3a (45–59 mL/min/ $1.73$  m<sup>2</sup>), G3b (30–44 mL/min/ $1.73$  m<sup>2</sup>), G4 (15–29 mL/min/ $1.73$  m<sup>2</sup>), and G5 ( $< 15$  mL/min/ $1.73$  m<sup>2</sup>).<sup>12</sup> For albuminuria, we used all available measurements of both dipstick and albumin-creatinine ratio, and categorized them according to KDIGO stages: A1 (ie, mildly increased albuminuria  $< 30$  mg/g), A2 (ie, moderately increased albuminuria 30–300 mg/g), and A3 (ie, severely increased albuminuria  $> 300$  mg/g).<sup>29</sup>

## Outcomes

Our primary study outcomes were kidney related: CKD progression was defined as the composite of kidney failure (initiation of dialysis or transplantation, sustained eGFR  $< 15$  mL/min/ $1.73$  m<sup>2</sup>) and a sustained decline of eGFR relative to baseline of more than 50%.<sup>30</sup> To reduce outcome misclassification bias owing to intrinsic eGFR variability and to confirm whether eGFR declines were sustained over time, we used a linear interpolation method, fitting one linear regression model per patient to all the patient's outpatient eGFR measurements.<sup>31</sup>

We also modeled these single outcomes separately. Worsening of albuminuria was defined by the presence during follow-up of at least 2 consecutive albuminuria tests denoting a KDIGO A category worse than baseline. Thus, patients who were classified as KDIGO A1 at baseline were followed for the occurrence of 2 consecutive albuminuria tests denoting KDIGO A2 or A3; patients were classified as KDIGO A2 for the occurrence of 2 consecutive albuminuria tests denoting KDIGO A3; and patients classified as KDIGO A3 at baseline were not considered for this outcome. Acute kidney injury (AKI) was defined as the composite of clinical diagnoses or transient creatinine elevations according to KDIGO criteria<sup>32</sup> following the algorithm developed by Hapca et al.<sup>33</sup> Patients with a history of AKI were not excluded, but their comorbidity history of AKI was adjusted for in our models. These outcomes were calculated at baseline and recalculated at each measure of HbA<sub>1c</sub> variability. Follow-up ended on the date of reaching end points, death, emigration, or December 31, 2018, whichever came first.

Secondary outcomes are those already evaluated in previous studies and here explored as a measure of internal validity.<sup>4,7</sup> These included all-cause mortality, major adverse cardiac events (MACE), and microvascular complications. MACE was defined as a composite of cardiovascular death, nonfatal myocardial infarction, heart failure, and stroke; patients with a history of these conditions were not excluded, but their comorbidity history was adjusted for in our models. Microvascular complications were defined as the composite of diabetic retinopathy, diabetic peripheral neuropathy, and diabetic foot ulcer; patients with any of these conditions at baseline were not excluded from the study, but we evaluated the risk of developing any of the other microvascular

complications during follow-up. For these outcomes, follow-up ended on the occurrence of an event, death, emigration or December 31, 2019, whichever came first.

## Statistical Analyses

Baseline characteristics are presented as mean  $\pm$  standard deviation (SD) or median (interquartile interval [IQI]) for continuous variables and as count (and proportion) for categorical variables.

We evaluated the association between baseline HVS groups and study outcomes using cause-specific Cox proportional hazards regression (with death considered as a competing event) and adjusted for the covariates listed earlier. Similarly, we evaluated outcomes associated with time-varying HVS through time-dependent Cox proportional hazards regression. To graphically depict the association between HVS (as a continuous variable) and study outcomes, we modeled HVS using natural cubic splines with 3 knots (at 25th, 50th, and 75th percentiles of the HVS distribution).

Study covariates had no missing values, to the extent that they were detected and measured in health care. The missing rate for albuminuria measurements was 18% at baseline and 9% during follow-up, for total cholesterol 3% at baseline and 2% during follow-up, and for low-density lipoprotein cholesterol 14% at baseline and 9% during follow-up. Because of the low proportion of missingness and current diabetes guideline recommendations to monitor these laboratory tests, we assumed missingness to be at random, and used chained equations by classification and regression trees (CART) to impute 10 complete datasets for each outcome separately.<sup>34</sup> The predictors included all covariates, the event indicator for the outcome, and the Nelson–Aalen estimator of the baseline and every updated HbA<sub>1c</sub> variability cumulative hazard. Adjusted analyses were performed on the 10 imputed datasets, and then the results were combined using Rubin's rules.<sup>35</sup>

*Subgroup analyses* were performed to evaluate the consistency of the association across baseline categories of age ( $< 60$  vs  $\geq 60$  years), sex (male vs female), eGFR categories, albuminuria categories, type 1/type 2 diabetes, baseline categories of HbA<sub>1c</sub>, and presence/absence of CVD.

*Supporting analyses* evaluated (1) whether outcomes associated with HVS differed across patients whose HbA<sub>1c</sub> was on target ( $\leq 53$  mmol/mol) or not, and (2) whether outcomes differed according to increasing or decreasing HbA<sub>1c</sub> variability trends. To that end, we calculated the linear regression slope of all HbA<sub>1c</sub> measurements during the 3-year window and stratified analyses by negative ( $< 0$  mmol/mol/year) and positive ( $\geq 0$  mmol/mol/year) slopes.

*Sensitivity analyses* were conducted to test the robustness of results: First, we used the coefficient of variation of HbA<sub>1c</sub> (HbA<sub>1c</sub>-CV) as an alternative study exposure. HbA<sub>1c</sub>-CV is

the ratio of intraindividual HbA<sub>1c</sub>-SD to intraindividual mean (HbA<sub>1c</sub>-mean). HbA<sub>1c</sub>-CV was categorized by using the 10th, 25th, 50th, 75th, and 90th percentiles as cutoff points, with the category of <10th percentile being the reference group. Second, we used attained age as the time scale instead of time-on-study to better capture the impact of age on study outcomes. Third, to avoid the impact of multiple HbA<sub>1c</sub> measures in a short space of time, we allocated 1 HbA<sub>1c</sub> measure for every 3-month period, using the median of all the outpatient HbA<sub>1c</sub> measures within that time (18). We also calculated the binned HVS as exposure.

Fourth, we repeated our main analysis among incident diabetes patients, defined as patients with a first-ever recorded diabetes diagnosis within 4 years from baseline. To that end we inspected medical records up to January 1997, the time at which International Classification of Diseases, Tenth Revision (ICD-10) was implemented in Sweden. Finally, the HbA<sub>1c</sub> variability calculation window was shortened and lengthened to 2 and 4 years, respectively, and the main analysis was repeated. Analyses were conducted in R software, version 3.4.3 (R Project for Statistical Computing).

## Results

### Baseline Characteristics

After applying inclusion and exclusion criteria, we evaluated 93,598 adults with diabetes who had at least 1 HbA<sub>1c</sub> outpatient test during 3 consecutive years to define baseline HbA<sub>1c</sub> variability (ie, baseline HVS; Fig S1). These patients underwent 527,015 outpatient HbA<sub>1c</sub> tests during the preceding 3-years in total, with a median number of 5 HbA<sub>1c</sub> tests per person.

Baseline characteristics are described in Table 1. The mean age of the participants was 65 ± 15 years, and 43.4% were women. The majority (87%) had type 2 diabetes; 19% had diabetic retinopathy, and 5% had diabetic peripheral neuropathy. Hypertension (68%) and psychiatric disorders (23%) were the most common comorbidities. Metformin (47%) and insulin (32%) were the most dispensed diabetes-controlling medications, and angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) (60%) were the most frequent nondiabetic medications.

A total of 17% of patients had CKD stages 3-5 at baseline, 23% had albuminuria stages A2/A3, and 1% had a history of diagnosed AKI. Patients with a higher HbA<sub>1c</sub> variability (higher HVS categories) tended to be younger and more often were women. There was also a higher proportion of patients with type 1 diabetes and patients with diabetes complications or more severe albuminuria. Conversely, patients across higher HVS categories had higher eGFR. The proportion of patients with hypertension or receiving ACEI or ARBs decreased in higher HVS categories, and the proportion of patients on insulin increased.

### HbA<sub>1c</sub> Variability Score and Kidney Outcomes

During a median follow-up of 5.2 (IQI, 3.0-8.0) years, there were 891,536 subsequent outpatient HbA<sub>1c</sub> tests, and at each test we recalculated HbA<sub>1c</sub> variability (time-varying exposure). The median number of HbA<sub>1c</sub> tests per person during the whole follow-up was 8, and the median number of HbA<sub>1c</sub> tests per patient per year was 2 (IQI, 1-2).

Study outcomes are shown in Table 2. Compared with baseline HVS (0-20%), higher HVS categories were associated with higher CKD progression risk as well as a higher risk for each of its individual components. For example, those with HVS of 81%-100% had a 60% higher risk of CKD progression (HR, 1.60 [95% CI, 1.47-1.74]), attributed both to a higher risk of kidney failure (HR, 1.57 [95% CI, 1.39-1.77]), and of declining eGFR by more than 50% (HR, 1.60 [95% CI, 1.47-1.75]). The association between baseline HVS (continuous variable) and the risk of CKD progression is graphically depicted in Figure 1A and shows a monotonic risk increase with larger HVS. We observed similar associations and risks magnitudes in time-varying analyses (Table 2; Fig S3A).

Compared with baseline HVS (0-20%), higher HVS categories were associated with higher risk of AKI. For example, those with HVS of 81-100% had a 23% higher AKI (HR, 1.23 [95% CI, 1.16-1.3]) (Fig 1B; Table 2). Time-varying analyses showed similar findings (Table 2; Fig S3B).

The risk of albuminuria progression was evaluated in a subset of patients (n = 72,728) who had baseline measures of albuminuria detected and were in the range of A1/A2 severity. In this subset, and during 4 (IQI 2-7) years of follow-up, 19,693 individuals progressed to a worse albuminuria category. Again, larger HVS was associated with higher risk of worsening of albuminuria in both baseline and time-varying analyses (Fig 1C; Table 2; Fig S3C).

### HbA<sub>1c</sub> Variability Score (HVS) and Secondary Outcomes

During 6.0 (IQI, 3-10), 5.3 (IQI, 2.7-9), and 4.0 (IQI, 1.9-7.8) years of follow-up, we identified 22,475 deaths, 21,675 MACEs, and 31,943 microvascular complications events, respectively. Compared with reference HVS (0-20%), larger HVS were consistently associated with a higher risk of all 3 outcomes, both in baseline and time-varying analyses (Table 3). For instance, compared with baseline HVS 0-20%, patients with HVS of 81%-100% had a 26% higher risk of all-cause death (HR, 1.26 [95% CI, 1.19-1.33]), 17% higher risk of MACE (HR, 1.17 [95% CI, 1.11-1.24]), and 39% higher risk of microvascular complications (HR, 1.39 [95% CI, 1.34-1.45]).

### Additional Analyses

Subgroup analyses generally showed similar results, both in direction and magnitude, except for some strata with limited sample size such as patients with CKD 4-5 or



**Table 1.** Baseline Characteristics of All Included Diabetic Patients, Overall and by Baseline Categories of HbA<sub>1c</sub> Variability

	Overall	Categories of 3-Year Baseline HVS				
		0-20%	20%-40%	40%-60%	60%-80%	80%-100%
N	93,598	38,344	19,824	17,552	11,204	6,674
Age, y	65 ± 15	68 ± 13	65 ± 15	63 ± 15	63 ± 16	62 ± 16
<b>Age categories</b>						
<50 y	12,749 (13.6%)	3,494 (9.1%)	2,832 (14.3%)	3,025 (17.2%)	2,051 (18.3%)	1,347 (20.2%)
50-59 y	15,497 (16.6%)	5,115 (13.3%)	3,343 (16.9%)	3,307 (18.8%)	2,297 (20.5%)	1,435 (21.5%)
60-60 y	26,671 (28.5%)	11,211 (29.2%)	5,689 (28.7%)	4,958 (28.2%)	3,022 (27.0%)	1,791 (26.8%)
70-79 y	23,722 (25.3%)	11,627 (30.3%)	4,933 (24.9%)	3,737 (21.3%)	2,240 (20.0%)	1,185 (17.8%)
≥80 y	14,959 (16.0%)	6,897 (18.0%)	3,027 (15.3%)	2,525 (14.4%)	1,594 (14.2%)	916 (13.7%)
Female	40,646 (43.4%)	18,199 (47.5%)	8,474 (42.7%)	7,170 (40.9%)	4,360 (38.9%)	2,443 (36.6%)
Type 1 diabetes mellitus	11,831 (12.6%)	3,071 (8.0%)	2,736 (13.8%)	2,947 (16.8%)	1,850 (16.5%)	1,227 (18.4%)
<b>Severity of Diabetes</b>						
Diabetic retinopathy	17,653 (18.9%)	4,781 (12.5%)	4,031 (20.3%)	4,253 (24.2%)	2,841 (25.4%)	1,747 (26.2%)
Diabetic peripheral neuropathy	4,541 (4.9%)	1,248 (3.3%)	1,054 (5.3%)	1,132 (6.4%)	719 (6.4%)	388 (5.8%)
Hypoglycemia history	557 (0.6%)	112 (0.3%)	118 (0.6%)	136 (0.8%)	117 (1.0%)	74 (1.1%)
<b>Laboratory Tests</b>						
Mean HbA <sub>1c</sub> , mmol/mol	52 [46-62]	46 [42-51]	54 [48-61]	58 [51-67]	63 [55-72]	65 [57-75]
eGFR, mL/min/1.73 m <sup>2</sup>	86 [69-98]	83 [68-94]	86 [68-98]	88 [69-100]	89 [70-102]	90 [73-103]
<b>eGFR categories</b>						
G1	38,567 (41.2%)	13,354 (34.8%)	8,369 (42.2%)	8,006 (45.6%)	5,383 (48.0%)	3,455 (51.8%)
G2	39,565 (42.3%)	18,756 (48.9%)	8,048 (40.6%)	6,598 (37.6%)	3,941 (35.2%)	2,222 (33.3%)
G3a	9,353 (10.0%)	4,145 (10.8%)	1,995 (10.1%)	1,655 (9.4%)	1,015 (9.1%)	543 (8.1%)
G3b	4,622 (4.9%)	1,666 (4.3%)	1,034 (5.2%)	958 (5.5%)	634 (5.7%)	330 (4.9%)
G4-5	1,491 (1.6%)	423 (1.1%)	378 (1.9%)	335 (1.9%)	231 (2.1%)	124 (1.9%)
<b>Albuminuria</b>						
A1	55,394 (59.2%)	24,105 (62.9%)	11,718 (59.1%)	10,007 (57.0%)	6,023 (53.8%)	3,541 (53.1%)
A2	17,334 (18.5%)	6,029 (15.7%)	3,711 (18.7%)	3,547 (20.2%)	2,477 (22.1%)	1,570 (23.5%)
A3	3,587 (3.8%)	921 (2.4%)	802 (4.0%)	867 (4.9%)	645 (5.8%)	352 (5.3%)
Missing	17,283 (18.5%)	7,289 (19.0%)	3,593 (18.1%)	3,131 (17.8%)	2,059 (18.4%)	1,211 (18.1%)
Total cholesterol, mmol/L	4.7 [4.1-5.4]	4.7 [4.2-5.4]	4.7 [4.1-5.3]	4.7 [4.1-5.3]	4.7 [4.1-5.3]	4.7 [4.1-5.4]
LDL-cholesterol, mmol/L	2.7 [2.2-3.3]	2.7 [2.2-3.3]	2.6 [2.1-3.2]	2.6 [2.1-3.3]	2.7 [2.1-3.3]	2.7 [2.2-3.3]
<b>Comorbidities</b>						
Hypertension	63,155 (67.5%)	27,078 (70.6%)	13,354 (67.4%)	11,390 (64.9%)	7,236 (64.6%)	4,097 (61.4%)
Myocardial infarction	12,266 (13.1%)	4,913 (12.8%)	2,702 (13.6%)	2,310 (13.2%)	1,509 (13.5%)	832 (12.5%)
Heart failure	11,184 (11.9%)	4,015 (10.5%)	2,529 (12.8%)	2,218 (12.6%)	1,550 (13.8%)	872 (13.1%)
Cerebrovascular disease	10,816 (11.6%)	4,400 (11.5%)	2,245 (11.3%)	1,973 (11.2%)	1,418 (12.7%)	780 (11.7%)
Peripheral vascular disease	6,334 (6.8%)	2,407 (6.3%)	1,397 (7.0%)	1,230 (7.0%)	889 (7.9%)	411 (6.2%)
Cancer	12,010 (12.8%)	5,257 (13.7%)	2,589 (13.1%)	2,175 (12.4%)	1,284 (11.5%)	705 (10.6%)
COPD	14,489 (15.5%)	6,045 (15.8%)	3,162 (16.0%)	2,669 (15.2%)	1,688 (15.1%)	925 (13.9%)

(Continued)

**Table 1 (Cont'd).** Baseline Characteristics of All Included Diabetic Patients, Overall and by Baseline Categories of HbA<sub>1c</sub> Variability

	Overall	Categories of 3-Year Baseline HVS				
		0-20%	20%-40%	40%-60%	60%-80%	80%-100%
Dementia	2,558 (2.7%)	831 (2.2%)	534 (2.7%)	518 (3.0%)	397 (3.5%)	278 (4.2%)
Liver disease	2,960 (3.2%)	998 (2.6%)	688 (3.5%)	586 (3.3%)	440 (3.9%)	248 (3.7%)
Psychiatric disorder	21,937 (23.4%)	8,668 (22.6%)	4,631 (23.4%)	4,203 (23.9%)	2,786 (24.9%)	1,649 (24.7%)
AKI history	1,289 (1.4%)	363 (0.9%)	300 (1.5%)	262 (1.5%)	230 (2.1%)	134 (2.0%)
<b>Ongoing Medication Use</b>						
Metformin	44,150 (47.2%)	15,935 (41.6%)	10,116 (51.0%)	8,877 (50.6%)	5,883 (52.5%)	3,339 (50.0%)
Sulfonylurea	15,275 (16.3%)	4,236 (11.0%)	3,683 (18.6%)	3,587 (20.4%)	2,376 (21.2%)	1,393 (20.9%)
Thiazolidinedione	1,365 (1.5%)	585 (1.5%)	296 (1.5%)	270 (1.5%)	130 (1.2%)	84 (1.3%)
α-Glucosidase inhibitor	286 (0.3%)	109 (0.3%)	59 (0.3%)	57 (0.3%)	42 (0.4%)	19 (0.3%)
Glinide	1,613 (1.7%)	544 (1.4%)	405 (2.0%)	344 (2.0%)	188 (1.7%)	132 (2.0%)
GLP1-RA	1,161 (1.2%)	165 (0.4%)	241 (1.2%)	326 (1.9%)	284 (2.5%)	145 (2.2%)
DPP4 inhibitor	2,924 (3.1%)	715 (1.9%)	696 (3.5%)	739 (4.2%)	488 (4.4%)	286 (4.3%)
SGLT2 inhibitor	333 (0.4%)	60 (0.2%)	79 (0.4%)	93 (0.5%)	56 (0.5%)	45 (0.7%)
Insulin	30,061 (32.1%)	6,197 (16.2%)	6,964 (35.1%)	7,909 (45.1%)	5,577 (49.8%)	3,414 (51.2%)
ACEI/ARB	56,500 (60.4%)	23,545 (61.4%)	12,175 (61.4%)	10,471 (59.7%)	6,677 (59.6%)	3,632 (54.4%)
Loop diuretic	15,939 (17.0%)	5,608 (14.6%)	3,607 (18.2%)	3,322 (18.9%)	2,221 (19.8%)	1,181 (17.7%)
Other diuretic	14,326 (15.3%)	6,220 (16.2%)	3,105 (15.7%)	2,546 (14.5%)	1,570 (14.0%)	885 (13.3%)
Other hypertensive agents	48,572 (51.9%)	21,060 (54.9%)	10,387 (52.4%)	8,674 (49.4%)	5,464 (48.8%)	2,987 (44.8%)
Statin	2,520 (2.7%)	797 (2.1%)	589 (3.0%)	543 (3.1%)	350 (3.1%)	241 (3.6%)
Platelet inhibitor	33,935 (36.3%)	13,880 (36.2%)	7,342 (37.0%)	6,368 (36.3%)	4,069 (36.3%)	2,276 (34.1%)
<b>Health Care Utilization in the 1 Year Prior</b>						
Primary care visits	3 [2-7]	4 [2-7]	4 [2-7]	3 [1-7]	3 [1-7]	3 [1-6]
Outpatient visits	2 [0-5]	2 [0-4]	2 [0-5]	2 [0-5]	2 [0-5]	2 [0-5]
Inpatient visits	0 [0-0]	0 [0-0]	0 [0-0]	0 [0-0]	0 [0-0]	0 [0-0]

Baseline characteristics are presented as mean ± SD or median [interquartile interval] for continuous variables and as count (and proportion) for categorical variables. Abbreviations: ACEI/ARB, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; AKI, acute kidney injury; COPD, chronic obstructive pulmonary disease; DPP4, dipeptidyl peptidase 4; eGFR, estimated glomerular filtration rate; GLP1-RA, glucagon-like peptide 1 receptor agonists; HbA<sub>1c</sub>, hemoglobin A<sub>1c</sub>; HVS, HbA<sub>1c</sub> variability score; LDL, low-density lipoprotein; SGLT2, sodium-glucose cotransporter 2.


**Table 2.** Primary Outcome of Risk of Kidney Outcomes Across Categories of HbA<sub>1c</sub> Variability

	Categories of 3-Year HVS				
	0-20%	20%-40%	40%-60%	60%-80%	80%-100%
<b>CKD Progression</b>					
Composite outcome					
No. of events/N <sup>a</sup>	2,693/38,344	1,963/19,824	1,905/17,552	1,367/11,204	783/6,674
Incidence rate/per 1,000 person-years <sup>a</sup>	12.27 (11.82-12.74)	17.08 (16.34-17.84)	18.63 (17.82-19.48)	21.72 (20.6-22.89)	20.86 (19.45-22.35)
Baseline HVS	1 (Ref)	1.25 (1.18-1.33)	1.31 (1.23-1.4)	1.45 (1.35-1.56)	1.6 (1.47-1.74)
Time-varying HVS	1 (Ref)	1.3 (1.21-1.39)	1.42 (1.32-1.52)	1.54 (1.42-1.66)	1.59 (1.45-1.74)
Kidney failure outcome					
No. of events/N <sup>a</sup>	1,225/38,344	1,047/19,824	1,043/17,552	733/11,204	421/6,674
Incidence rate/per 1,000 person-years <sup>a</sup>	5.54 (5.24-5.85)	9 (8.47-9.55)	10.07 (9.48-10.69)	11.47 (10.67-12.31)	11.03 (10.03-12.11)
Baseline HVS	1 (Ref)	1.31 (1.21-1.43)	1.34 (1.23-1.47)	1.43 (1.29-1.58)	1.57 (1.39-1.77)
Time-varying HVS	1 (Ref)	1.28 (1.18-1.4)	1.37 (1.25-1.5)	1.48 (1.34-1.63)	1.41 (1.25-1.59)
50% decline of eGFR outcome					
No. of events/N <sup>a</sup>	2,608/38,344	1,887/19,824	1,833/17,552	1,318/11,204	755/6,674
Incidence rate/per 1,000 person-years <sup>a</sup>	11.87 (11.43-12.33)	16.37 (15.65-17.12)	17.88 (17.08-18.71)	20.88 (19.78-22.02)	20.08 (18.7-21.54)
Baseline HVS	1 (Ref)	1.24 (1.17-1.32)	1.32 (1.23-1.4)	1.46 (1.36-1.57)	1.6 (1.47-1.75)
Time-varying HVS	1 (Ref)	1.31 (1.21-1.41)	1.48 (1.37-1.6)	1.65 (1.51-1.79)	1.72 (1.56-1.9)
<b>AKI</b>					
No. of events/N <sup>a</sup>	7,912/38,344	4,886/19,824	4,554/17,552	3,132/11,204	1,742/6,674
Incidence rate/per 1,000 person-years <sup>a</sup>	39.18 (38.33-40.05)	46.87 (45.57-48.19)	49.43 (48.02-50.88)	55.62 (53.7-57.58)	51.22 (48.88-53.66)
Baseline HVS	1 (Ref)	1.12 (1.08-1.16)	1.17 (1.13-1.22)	1.22 (1.17-1.27)	1.23 (1.16-1.3)
Time-varying HVS	1 (Ref)	1.16 (1.12-1.2)	1.23 (1.19-1.28)	1.28 (1.22-1.34)	1.33 (1.26-1.41)
<b>Worsening of Albuminuria</b>					
No. of events/N <sup>a</sup>	7,331/30,134	4,388/15,429	3,951/13,554	2,519/8,500	1,504/5,111
Incidence rate/per 1,000 person-years <sup>a</sup>	52.78 (51.59-54)	62.3 (60.49-64.16)	63.22 (61.28-65.21)	66.83 (64.27-69.47)	65.13 (61.92-68.46)
Baseline HVS	1 (Ref)	1.17 (1.13-1.22)	1.21 (1.16-1.26)	1.26 (1.2-1.32)	1.28 (1.21-1.36)
Time-varying HVS	1 (Ref)	1.21 (1.16-1.26)	1.26 (1.2-1.31)	1.31 (1.25-1.38)	1.31 (1.23-1.39)

Values are hazard ratios and 95% CI unless otherwise indicated. Models were adjusted for age, sex, diabetes type, diabetic retinopathy, diabetic peripheral neuropathy, history of hypoglycemia, hypertension, myocardial infarction, heart failure, cerebrovascular disease, peripheral vascular disease, cancer, chronic obstructive pulmonary disease, dementia, liver disease, psychiatric disorder, metformin, sulfonylurea, thiazolidinedione, alpha glucosidase inhibitor, glinide, glucagon-like peptide 1 receptor agonists, dipeptidyl peptidase 4 inhibitors, sodium-glucose cotransporter 2 inhibitors, insulin, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, loop diuretics, other diuretics, other hypertensives, statins, platelet inhibitors, mean hemoglobin A<sub>1c</sub>, eGFR, albuminuria category, total cholesterol, low-density lipoprotein, number of primary care visits, number of outpatient visits, number of hospitalizations. For the outcome of AKI, history of AKI was additionally included in the list of covariates; for the outcome of progression of albuminuria, persons with albuminuria A3 or untested were not included. Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HVS, hemoglobin A<sub>1c</sub> variability score; Ref, reference value.

<sup>a</sup>Number of events, patients and incidence rate considered in time-fixed analyses.





**Figure 1.** Associations between 3-year baseline HbA<sub>1c</sub> variability score with kidney-related outcomes. A: CKD progression; B: AKI; C: Worsening of albuminuria. Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; HbA<sub>1c</sub>, hemoglobin A<sub>1c</sub>.

patients with albuminuria A3. Risk associations increased across higher HVS categories regardless of whether attained HbA<sub>1c</sub> was on target or not, and whether variability was increasing or decreasing (Tables S3-S5). When HbA<sub>1c</sub>-CV was used as an alternative metric of HbA<sub>1c</sub> variability, we observed similar linear associations with study outcome (Tables S6-S7). Using attained age as the time scale produced similar results, as well as averaging HbA<sub>1c</sub> in 3-month periods or using binned HVS as a measure of HbA<sub>1c</sub> variability. Restricting the analysis to the >40,000 patients with an incident diabetes diagnosis or estimating the 2-year or 4-year HbA<sub>1c</sub> variability produced results consistent with our main analysis (Tables S8-S12).

## Discussion

Poor glycemic control is an established contributor to the occurrence and progression of CKD,<sup>9</sup> but whether long-

term visit-to-visit variability in glycemic control is associated with kidney outcomes is not well studied. By evaluating the long-term trajectories of glycemic control in almost 100,000 persons with diabetes, we observed a consistent and linear association between high HbA<sub>1c</sub> variability and the risks of CKD progression, worsening of albuminuria, and AKI. Results were robust to adjustment for mean HbA<sub>1c</sub> and multiple covariates. We saw similar associations across a variety of subgroup and sensitivity analyses, including patients with and without manifest CKD.

Our finding of an association between HbA<sub>1c</sub> variability and the risk of AKI is novel and is consistent with mechanistic evidence suggesting a role for hyperglycemia in increasing AKI susceptibility in diabetes.<sup>36-38</sup> Our finding of an association between HbA<sub>1c</sub> variability and the risk of CKD progression or worsening of albuminuria is confirmatory, expanding the previous observations we will discuss. The strengths of our analysis include its large sample size (more than 10-fold larger than previous studies), inclusion of persons with type 1 and type 2 diabetes, and unique setting, involving real-world patients from a country with universal tax-funded health care, which minimizes selection bias from disparate access to health care.

Some previous studies have reported an association between HbA<sub>1c</sub> variability and the risk of worsening albuminuria or developing incident CKD.<sup>11-20</sup> These studies typically evaluated a single baseline assessment of HbA<sub>1c</sub> variability, and study outcomes were not harmonized, precluding comparisons. They were performed in predominantly smaller research cohorts and through post hoc analyses of clinical trials. In these settings, HbA<sub>1c</sub> variability is lower compared with that of our study, which includes a more heterogeneous population of persons seeking health care. Whereas previous studies used the standard deviation of repeated HbA<sub>1c</sub> tests as a measure of variability, we opted for the HVS as it accounts for the number of HbA<sub>1c</sub> tests in its calculation. This method aligns with recent studies evaluating glycemic variability and other macro- and microvascular complications<sup>4-7</sup> and may be more relevant to routine care settings, given that sicker patients tend to have more frequent contact with the health care system and more frequent HbA<sub>1c</sub> testing. The windows of ascertainment of HbA<sub>1c</sub> variability for most previous studies was 1 or 2 years, which may underestimate the importance of HbA<sub>1c</sub> variability, given that in the absence of complications contact with the health care system may be infrequent.

Our study has clinical implications. The evidence for current guideline recommendations derives from clinical trials that focus on HbA<sub>1c</sub> as the definitive measure of efficacy of an intervention. For instance, intensive glycemic control with the goal of achieving near-normoglycemia delayed the onset and progression of albuminuria and reduced eGFR in patients with type 1<sup>39</sup> and type 2 diabetes,<sup>2</sup> supporting the conclusion that glycemic control

**Table 3.** Risk of Secondary Outcomes Across Categories of HbA<sub>1c</sub> Variability

	Categories of 3-Year HVS				
	0-20%	20%-40%	40%-60%	60%-80%	80%-100%
<b>All-cause death</b>					
No. of events/N <sup>a</sup>	8,172/41,329	4,923/20,949	4,568/18,460	3,061/11,758	1,751/6,983
Incidence rate/per 1,000 person-years <sup>a</sup>	31.97 (31.28-32.67)	36.87 (35.85-37.91)	38.5 (37.4-39.63)	41.64 (40.19-43.12)	39.96 (38.13-41.85)
Baseline HVS	1 (Ref)	1.13 (1.09-1.17)	1.21 (1.16-1.26)	1.23 (1.18-1.28)	1.26 (1.19-1.33)
Time-varying HVS	1 (Ref)	1.23 (1.19-1.28)	1.33 (1.28-1.39)	1.45 (1.39-1.52)	1.63 (1.55-1.71)
<b>MACE</b>					
No. of events/N <sup>a</sup>	8,328/41,329	4,731/20,949	4,206/18,460	2,860/11,758	1,550/6,983
Incidence rate/per 1,000 person-years <sup>a</sup>	35.61 (34.85-36.38)	38.98 (37.89-40.1)	39.19 (38.02-40.38)	43.16 (41.61-44.76)	38.64 (36.76-40.59)
Baseline HVS	1 (Ref)	1.1 (1.06-1.14)	1.14 (1.1-1.19)	1.18 (1.13-1.24)	1.17 (1.11-1.24)
Time-varying HVS	1 (Ref)	1.14 (1.1-1.18)	1.19 (1.15-1.24)	1.19 (1.14-1.24)	1.31 (1.24-1.38)
<b>Microvascular complications</b>					
No. of events/N <sup>a</sup>	9,784/41,329	7,217/20,949	7,145/18,460	4,813/11,758	2,984/6,983
Incidence rate/per 1,000 person-years <sup>a</sup>	46.07 (45.17-46.99)	72.99 (71.33-74.68)	84.78 (82.84-86.76)	94.46 (91.83-97.15)	99.43 (95.92-103.02)
Baseline HVS	1 (Ref)	1.28 (1.24-1.32)	1.34 (1.29-1.38)	1.39 (1.34-1.44)	1.39 (1.34-1.45)
Time-varying HVS	1 (Ref)	1.26 (1.23-1.3)	1.36 (1.32-1.41)	1.35 (1.3-1.4)	1.39 (1.33-1.45)

Values are hazard ratios and 95% CI unless otherwise indicated. Models were adjusted for age, sex, diabetes type, diabetic retinopathy, diabetic peripheral neuropathy, history of hypoglycemia, hypertension, myocardial infarction, heart failure, cerebrovascular disease, peripheral vascular disease, cancer, chronic obstructive pulmonary disease, dementia, liver disease, psychiatric disorder, metformin, sulfonylurea, thiazolidinedione, alpha glucosidase inhibitor, glinide, glucagon-like peptide 1 receptor agonists, dipeptidyl peptidase 4 inhibitors, sodium-glucose cotransporter 2 inhibitors, insulin, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, loop diuretics, other diuretics, other hypertensives, statins, platelet inhibitors, mean hemoglobin A<sub>1c</sub>, eGFR, albuminuria category, total cholesterol, low-density lipoprotein, number of primary care visits, number of outpatient visits, number of hospitalizations. Abbreviations: AKI, acute kidney disease; HbA<sub>1c</sub>, hemoglobin A<sub>1c</sub>; HVS, hemoglobin A<sub>1c</sub> variability score; MACE, major adverse cardiovascular events; Ref, reference value.

<sup>a</sup>Number of events, patients, and incidence rate considered in time-fixed analyses.

itself helps prevent CKD and its progression. Although target HbA<sub>1c</sub> levels in people with CKD are still controversial,<sup>9,40</sup> the current guidelines emphasize individualized HbA<sub>1c</sub> targets and possibly less intensive glycemic control for these persons. However, HbA<sub>1c</sub> reflects average glycemia without regard to glycemic variability, which is associated with higher risk of hypoglycemia on average.<sup>41</sup> Thus, our work emphasizes the value of going “beyond HbA<sub>1c</sub>”: patients with greater HbA<sub>1c</sub> variability should be considered high risk over and above their level of glycemic control.

Because HbA<sub>1c</sub> variability is associated with the quality of patient care,<sup>42</sup> it is possible to reduce the HbA<sub>1c</sub> variability in clinical practice. Interventions that reduce variability in HbA<sub>1c</sub> may include education programs on diet and lifestyle, closer contact with a dietitian, and modifying antidiabetic medication regimens. Most people with high variability in our study were on insulin and might benefit from enhanced teaching in insulin administration and incorporation of emerging technologies that integrate continuous glucose monitoring, food intake, and insulin dose.<sup>40</sup>

Interestingly, contact with the health care system tended to be lower in patients with high HbA<sub>1c</sub> variability, suggesting that this high-risk population might benefit from targeted monitoring strategies.<sup>4-7</sup> Although it was not feasible in our current analysis, it would be interesting to evaluate whether adherence or changes in antidiabetic treatments reduce HbA<sub>1c</sub> variability and can explain the improved outcomes with some of these agents. Both glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce HbA<sub>1c</sub> variability compared with standard of care,<sup>43</sup> together with additional benefits to prevent kidney and cardiovascular complications.<sup>44-46</sup>

We acknowledge additional limitations. We lacked information on diet, body mass index, volume status, and diabetes duration; however, our sensitivity analysis among >40,000 patients with incident diabetes showed similar findings. Our definition of albuminuria worsening considers quantitatively large changes across KDIGO A thresholds and may underestimate risks. Our population was predominantly White, and additional studies in more diverse populations are needed. HbA<sub>1c</sub> tests may be less reliable in persons with advanced CKD owing to the influence of CKD-related anemia and the life spans of red cells with subsequent alterations in hemoglobin glycation percentages,<sup>47</sup> or the interference from posttranslational protein carbamylation, which can increase in states of high urea burden such as CKD.<sup>48</sup> As recently suggested, the extent of both these abnormalities may impact on HbA<sub>1c</sub>'s predictive abilities for the risk of CKD progression.<sup>49</sup> Finally, all limitations inherent to observational studies apply.

To conclude, the findings of this study support a role for long-term glycemic variability in the development of kidney complications and illustrates the potential usefulness of this metric for risk stratification at the bedside beyond a single HbA<sub>1c</sub> test.

## Supplementary Material

### Supplementary File (PDF)

**Figure S1:** Flow chart of patient selection into the study.

**Figure S2:** Illustration of time-varying design.

**Figure S3:** Associations between 3-year time-varying HbA<sub>1c</sub> variability score with kidney-related outcomes.

**Table S1:** Definition of study outcomes.

**Table S2:** Definition of study covariates.

**Table S3:** Subgroup analyses for the risk of CKD progression across categories of HbA<sub>1c</sub> variability.

**Table S4:** Subgroup analyses for the risk of AKI across categories of HbA<sub>1c</sub> variability.

**Table S5:** Subgroup analyses for the risk of worsening of albuminuria across categories of HbA<sub>1c</sub> variability.

**Table S6:** Baseline characteristics of all included patients, overall and by categories of baseline HbA<sub>1c</sub>-CV.

**Table S7:** HRs and 95% CI for the risk of different adverse clinical outcomes across categories of 3-year HbA<sub>1c</sub>-CV.

**Table S8:** Sensitivity analysis 1: HRs and 95% CI for the risk of adverse clinical outcomes across categories of HbA<sub>1c</sub> variability when age is used as the time scale.

**Table S9:** Sensitivity analysis 2: HRs and 95% CI for the risk of different adverse clinical outcomes across categories of HbA<sub>1c</sub> variability averaging HbA<sub>1c</sub> measurements every 3-months.

**Table S10:** Sensitivity analysis 3: HRs and 95% CI for the risk of adverse clinical outcomes across categories of HbA<sub>1c</sub> variability among patients with incident diabetes.

**Table S11:** Sensitivity analysis 4: HRs and 95% CI for the risk of different adverse clinical outcomes across categories of HbA<sub>1c</sub> variability (shortening the ascertainment window to 2 years).

**Table S12:** Sensitivity analysis 4: HRs and 95% CI for the risk of adverse clinical outcomes across categories of HbA<sub>1c</sub> variability (enlarging the ascertainment window to 4 years).

## Article Information

**Authors' Full Names and Academic Degrees:** Yang Xu, PharmD, Shujie Dong, MEd, Edouard L. Fu, MD, PhD, Arvid Sjölander, PhD, Morgan E. Grams, MD, PhD, Elizabeth Selvin, MD, PhD, and Juan Jesus Carrero, PharmD.

**Authors' Affiliations:** Peking University Clinical Research Institute, Peking University First Hospital (YX), and Department of Pharmacy, Peking University Third Hospital (SD), Beijing, People's Republic of China; Department of Medical Epidemiology and Biostatistics (YX, ELF, AS, JJC), Karolinska Institute; Division of Nephrology, Department of Clinical Sciences, Danderyd Hospital (JJC), Stockholm, Sweden; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Harvard University, Boston, Massachusetts (ELF); Department of Medicine, New York University Grossman School of Medicine, New York, New York (MEG); and Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (ES).

**Address for Correspondence:** Yang Xu, PhD, Peking University Clinical Research Institute, Peking University First Hospital, No. 8 Xishiku St, Xicheng District, 100034, Beijing, People's Republic of China. Email: xuyang\_pucr@bjmu.edu.cn

**Authors' Contributions:** Study design: YX, JJC; statistical analysis plan: YX; data analysis: all authors; study supervision: JJC. Each

author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual's own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate.

**Support:** Research reported in this publication was supported by the Swedish Research Council (#2019-01059), the Swedish Heart-Lung Foundation, and the Westman Foundation. Dr Fu acknowledges support by a Rubicon Grant of the Netherlands Organization for Scientific Research (NWO). Dr Grams is supported by US National Institutes of Health grants K24 HL155861, R01 DK115534, and R01 DK100446. The funding sources had no role in the design and conduct of the study, analysis or interpretation of the data, and preparation or final approval of the manuscript before publication.

**Financial Disclosure:** The authors declare that they have no relevant financial interests.

**Peer Review:** Received October 13, 2022. Evaluated by 2 external peer reviewers, with direct editorial input from a Statistics/Methods Editor, an Associate Editor, and a Deputy Editor who served as Acting Editor-in-Chief. Accepted in revised form March 8, 2023. The involvement of an Acting Editor-in-Chief was to comply with AJKD's procedures for potential conflicts of interest for editors, described in the Information for Authors & Journal Policies.

## References

1. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *Lancet*. 2009;373(9677):1765-1772. doi:10.1016/S0140-6736(09)60697-8
2. Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. *Lancet Diabetes Endocrinol*. 2017;5(6):431-437. doi:10.1016/S2213-8587(17)30104-3
3. Fang HJ, Zhou YH, Tian YJ, Du HY, Sun YX, Zhong LY. Effects of intensive glucose lowering in treatment of type 2 diabetes mellitus on cardiovascular outcomes: a meta-analysis of data from 58,160 patients in 13 randomized controlled trials. *Int J Cardiol*. 2016;218:50-58. doi:10.1016/j.ijcard.2016.04.163
4. Sheng C-S, Tian J, Miao Y, et al. Prognostic significance of long-term HbA<sub>1c</sub> variability for all-cause mortality in the ACCORD trial. *Diabetes Care*. 2020;43(6):1185-1190. doi:10.2337/dc19-2589
5. Li S, Nemeth I, Donnelly L, Hapca S, Zhou K, Pearson ER. Visit-to-visit HbA<sub>1c</sub> variability is associated with cardiovascular disease and microvascular complications in patients with newly diagnosed type 2 diabetes. *Diabetes Care*. 2020;43(2):426. doi:10.2337/dc19-0823
6. Forbes A, Murrells T, Mulnier H, Sinclair AJ. Mean HbA<sub>1c</sub>, HbA<sub>1c</sub> variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study. *Lancet Diabetes Endocrinol*. 2018;6(6):476-486. doi:10.1016/S2213-8587(18)30048-2
7. Critchley JA, Carey IM, Harris T, DeWilde S, Cook DG. Variability in glycated hemoglobin and risk of poor outcomes among people with type 2 diabetes in a large primary care cohort study. *Diabetes Care*. 2019;42(12):2237-2246. doi:10.2337/dc19-0848
8. De Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. *JAMA*. 2011;305(24):2532-2539. doi:10.1001/jama.2011.861
9. Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. *Kidney Int*. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019
10. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. *Diabetes Care*. 2014;37(10):2864-2883. doi:10.2337/dc14-1296
11. Ceriello A, De Cosmo S, Rossi MC, et al. Variability in HbA<sub>1c</sub>, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. *Diabetes Obes Metab*. 2017;19(11):1570-1578. doi:10.1111/dom.12976
12. Hsu CC, Chang HY, Huang MC, et al. HbA<sub>1c</sub> variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study. *Diabetologia*. 2012;55(12):3163-3172. doi:10.1007/s00125-012-2700-4
13. Kilpatrick ES, Rigby AS, Atkin SL. A<sub>1c</sub> variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. *Diabetes Care*. 2008;31(11):2198-2202. doi:10.2337/dc08-0864
14. Lin CC, Chen CC, Chen FN, et al. Risks of diabetic nephropathy with variation in hemoglobin A<sub>1c</sub> and fasting plasma glucose. *Am J Med*. 2013;126(11). doi:10.1016/j.amjmed.2013.04.015. 1017 e1011-1010.
15. Luk AO, Ma RC, Lau ES, et al. Risk association of HbA<sub>1c</sub> variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry. *Diabetes Metab Res Rev*. 2013;29(5):384-390. doi:10.1002/dmrr.2404
16. Penno G, Solini A, Bonora E, et al. HbA<sub>1c</sub> variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency and Cardiovascular Events (RIACE) Italian multicenter study. *Diabetes Care*. 2013;36(8):2301-2310. doi:10.2337/dc12-2264
17. Rodriguez-Segade S, Rodriguez J, Garcia Lopez JM, Casanueva FF, Camina F. Intrapersonal HbA<sub>1c</sub> variability and the risk of progression of nephropathy in patients with type 2 diabetes. *Diabet Med*. 2012;29(12):1562-1566. doi:10.1111/j.1464-5491.2012.03767.x
18. Sugawara A, Kawai K, Motohashi S, et al. HbA<sub>1c</sub> variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2. *Diabetologia*. 2012;55(8):2128-2131. doi:10.1007/s00125-012-2572-7
19. Waden J, Forsblom C, Thorn LM, et al. A<sub>1c</sub> variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. *Diabetes*. 2009;58(11):2649-2655. doi:10.2337/db09-0693
20. Yang YF, Li TC, Li CI, et al. Visit-to-visit glucose variability predicts the development of end-stage renal disease in type 2 diabetes: 10-year follow-up of Taiwan Diabetes Study. *Medicine (Baltimore)*. 2015;94(44):e1804. doi:10.1097/MD.0000000000001804
21. Sawhney S, Mitchell M, Marks A. Long-term prognosis after acute kidney injury (AKI): what is the role of baseline kidney function and recovery? A systematic review. *BMJ Open*. 2015;5(1):e006497. doi:10.1136/bmjopen-2014-006497
22. James MT, Grams ME, Woodward M, et al. A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury. *Am J Kidney Dis*. 2015;66(4):602-612. doi:10.1053/j.ajkd.2015.02.338



23. Ronco C, Bellomo R, Kellum JA. Acute kidney injury. *Lancet*. 2019;394(10212):1949-1964. doi:10.1016/s0140-6736(19)32563-2
24. Xu Y, Surapaneni A, Alkas J, et al. Glycemic control and the risk of acute kidney injury in patients with type 2 diabetes and chronic kidney disease: parallel population-based cohort studies in U.S. and Swedish routine care. *Diabetes Care*. 2020;43(12):2975-2982. doi:10.2337/dc20-1588
25. Carrero JJ, Elinder CG. The Stockholm CREAtinine Measurements (SCREAM) project: fostering improvements in chronic kidney disease care. *J Intern Med*. 2022;291(3):254-268. doi:10.1111/joim.13418
26. Laugesen K, Ludvigsson JF, Schmidt M, et al. Nordic Health Registry-based research: a review of health care systems and key registries. *Clin Epidemiol*. 2021;13:533-554. doi:10.2147/lep.S314959
27. Socialstyrelsen. Nationella riktlinjer för diabetesvård: stöd för styrning och ledning [National guidelines for diabetes care: support for governance and management]. Socialstyrelsen; 2018. <https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/nationella-riktlinjer/2018-10-25.pdf>
28. Viss. Diabetes—omvårdnad [Diabetes: nursing]. Updated February 2022. [https://viss.nu/kunskapsstod/omvardnadsprogram/diabetes—omvardnad](https://viss.nu/kunskapsstod/omvardnadsprogram/diabetes--omvardnad)
29. Sumida K, Nadkarni GN, Grams ME, et al. Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis. *Ann Intern Med*. 2020;173(6):426-435. doi:10.7326/m20-0529
30. Levey AS, Gansevoort RT, Coresh J, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. *Am J Kidney Dis*. 2020;75(1):84-104. doi:10.1053/j.ajkd.2019.06.009
31. Zee J, Mansfield S, Mariani LH, Gillespie BW. Using all longitudinal data to define time to specified percentages of estimated GFR decline: a simulation study. *Am J Kidney Dis*. 2019;73(1):82-89. doi:10.1053/j.ajkd.2018.07.009
32. Kellum JA, Lameire N, Aspelin P, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group: KDIGO 2012 clinical practice guideline for acute kidney injury. *Kidney Int Suppl*. 2012;2:1-138. doi:10.1038/kisup.2012.1
33. Hapca S, Siddiqui MK, Kwan RSY, et al. The relationship between AKI and CKD in patients with type 2 diabetes: an observational cohort study. *J Am Soc Nephrol*. 2021;32(1):138. doi:10.1681/ASN.2020030323
34. Van Buuren S, Oudshoorn CG. *Multivariate Imputation by Chained Equations: MICE V1.0 User's Manual*. Report PG/VGZ/00.038. TNO Prevention and Health; 2000. <https://stefvanbuuren.name/publications/MICE%20V1.0%20Manual%20TNO00038%202000.pdf>
35. Harel O, Zhou X-H. Multiple imputation: review of theory, implementation and software. *Stat Med*. 2007;26(16):3057-3077. doi:10.1002/sim.2787
36. Vanhorebeek I, Gunst J, Ellger B, et al. Hyperglycemic kidney damage in an animal model of prolonged critical illness. *Kidney Int*. 2009;76(5):512-520. doi:10.1038/ki.2009.217
37. Peng J, Li X, Zhang D, et al. Hyperglycemia, p53, and mitochondrial pathway of apoptosis are involved in the susceptibility of diabetic models to ischemic acute kidney injury. *Kidney Int*. 2015;87(1):137-150. doi:10.1038/ki.2014.226
38. Forbes JM, McCarthy DA, Kassianos AJ, et al. T-cell expression and release of kidney injury molecule-1 in response to glucose variations initiates kidney injury in early diabetes. *Diabetes*. 2021;70(8):1754-1766. doi:10.2337/db20-1081
39. The DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. *N Engl J Med*. 2011;365(25):2366-2376. doi:10.1056/NEJMoa1111732
40. American Diabetes Association Professional Practice Committee. Standards of medical care in diabetes—2022. *Diabetes Care*. 2021;45(suppl 1):S1-S264. doi:10.2337/dc22-Sint
41. Zhou JJ, Koska J, Bahn G, Reaven P. Glycaemic variation is a predictor of all-cause mortality in the Veteran Affairs Diabetes Trial. *Diabetes Vasc Dis Res*. 2019;16(2):178-185. doi:10.1177/1479164119827598
42. Ceriello A, Rossi MC, De Cosmo S, et al. Overall quality of care predicts the variability of key risk factors for complications in type 2 diabetes: an observational, longitudinal retrospective study. *Diabetes Care*. 2019;42(4):514-519. doi:10.2337/dc18-1471
43. Lee H, Park SE, Kim EY. Glycemic Variability impacted by SGLT2 inhibitors and GLP 1 agonists in patients with diabetes mellitus: a systematic review and meta-analysis. *J Clin Med*. 2021;10(18):4078. doi:10.3390/jcm10184078
44. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med*. 2019;380(24):2295-2306. doi:10.1056/NEJMoa1811744
45. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. *Lancet Diabetes Endocrinol*. 2021;9(10):653-662. doi:10.1016/S2213-8587(21)00203-5
46. Zhao M, Sun S, Huang Z, Wang T, Tang H. Network meta-analysis of novel glucose-lowering drugs on risk of acute kidney injury. *Clin J Am Soc Nephrol*. 2021;16(1):70. doi:10.2215/CJN.11220720
47. Ng JM, Cooke M, Bhandari S, Atkin SL, Kilpatrick ES. The effect of iron and erythropoietin treatment on the A<sub>1c</sub> of patients with diabetes and chronic kidney disease. *Diabetes Care*. 2010;33(11):2310-2313. doi:10.2337/dc10-0917
48. Flückiger R, Harmon W, Meier W, Loo S, Gabbay KH. Hemoglobin carbamylation in uremia. *N Engl J Med*. 1981;304(14):823-827. doi:10.1056/NEJM198104023041406
49. Tang M, Berg A, Rhee EP, et al. The impact of carbamylation and anemia on HbA<sub>1c</sub>'s association with renal outcomes in patients with diabetes and chronic kidney disease. *Diabetes Care*. 2022;46(1):130-137. doi:10.2337/dc22-1399